These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23112123)

  • 1. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
    Dagley LF; Emili A; Purcell AW
    Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics technologies for biomarker discovery in multiple sclerosis.
    Singh V; Hintzen RQ; Luider TM; Stoop MP
    J Neuroimmunol; 2012 Jul; 248(1-2):40-7. PubMed ID: 22129845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten years of proteomics in multiple sclerosis.
    Farias AS; Pradella F; Schmitt A; Santos LM; Martins-de-Souza D
    Proteomics; 2014 Mar; 14(4-5):467-80. PubMed ID: 24339438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
    Ekegren T; Hanrieder J; Bergquist J
    J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CE-MS in biomarker discovery, validation, and clinical application.
    Mischak H; Schanstra JP
    Proteomics Clin Appl; 2011 Feb; 5(1-2):9-23. PubMed ID: 21280234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to MS bedside: challenges translating biomarker discovery to clinical practice.
    Rajasekharan S; Bar-Or A;
    J Neuroimmunol; 2012 Jul; 248(1-2):66-72. PubMed ID: 22381245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New technologies for biomarker discovery in multiple sclerosis.
    Comabella M; Racke MK
    J Neuroimmunol; 2012 Jul; 248(1-2):1. PubMed ID: 22726889
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery.
    Elschenbroich S; Kislinger T
    Mol Biosyst; 2011 Feb; 7(2):292-303. PubMed ID: 20976349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery.
    Fang X; Balgley BM; Lee CS
    Electrophoresis; 2009 Dec; 30(23):3998-4007. PubMed ID: 19960464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-free mass spectrometry-based proteomics for biomarker discovery and validation.
    Pham TV; Piersma SR; Oudgenoeg G; Jimenez CR
    Expert Rev Mol Diagn; 2012 May; 12(4):343-59. PubMed ID: 22616700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis.
    Villoslada P; Baranzini S
    J Neuroimmunol; 2012 Jul; 248(1-2):58-65. PubMed ID: 22281286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted proteomics strategy applied to biomarker evaluation.
    Kim YJ; Gallien S; van Oostrum J; Domon B
    Proteomics Clin Appl; 2013 Dec; 7(11-12):739-47. PubMed ID: 24123942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Thamilarasan M; Koczan D; Hecker M; Paap B; Zettl UK
    Autoimmun Rev; 2012 Jan; 11(3):174-9. PubMed ID: 21621006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application.
    Mischak H; Delles C; Klein J; Schanstra JP
    Adv Chronic Kidney Dis; 2010 Nov; 17(6):493-506. PubMed ID: 21044772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.
    Whiteaker JR; Zhang H; Zhao L; Wang P; Kelly-Spratt KS; Ivey RG; Piening BD; Feng LC; Kasarda E; Gurley KE; Eng JK; Chodosh LA; Kemp CJ; McIntosh MW; Paulovich AG
    J Proteome Res; 2007 Oct; 6(10):3962-75. PubMed ID: 17711321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers.
    Rithidech KN; Honikel L; Milazzo M; Madigan D; Troxell R; Krupp LB
    Mult Scler; 2009 Apr; 15(4):455-64. PubMed ID: 19324981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can proteomics elucidate the complexity of multiple sclerosis?
    Farias AS; Santos LM
    Proteomics Clin Appl; 2015 Oct; 9(9-10):844-7. PubMed ID: 25980360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.
    Singh V; Tripathi A; Dutta R
    Proteomics; 2019 Aug; 19(16):e1800335. PubMed ID: 31119864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Industrialized MS-based proteomics in the search for circulating biomarkers.
    Migneault I; Hunter JM
    Bioanalysis; 2009 Sep; 1(6):1149-63. PubMed ID: 21083081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic biomarker discovery: it's more than just mass spectrometry.
    Blonder J; Issaq HJ; Veenstra TD
    Electrophoresis; 2011 Jun; 32(13):1541-8. PubMed ID: 21557261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.